Business Wire

Magnus Carlsen and Christian Pulisic Talk About Similarities in Football and Chess

13.7.2023 15:00:00 EEST | Business Wire | Press release

Share

Global Sports company PUMA announces a collaboration between five-time World Chess Champion Magnus Carlsen and professional football player Christian Pulisic. Two sport icons came together on a football pitch to have a conversation about the differences and similarities between chess and football.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230713204362/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Global Sports company PUMA brought together five-time World Chess Champion Magnus Carlsen and professional football player Christian Pulisic, as the two sport icons met on a football pitch to have a conversation about the differences and similarities between chess and football. (Photo: Business Wire)

What can a football athlete and a chess player teach one another? The conversation between Magnus and Christian only shows that there are plenty of things that are relevant for both disciplines. “I am an attacking player who likes to be creative and to put defenders on their back foot. I like to be very aggressive and direct towards goals, so that's really my style,” said Pulisic. When playing football or chess, it is important to avoid critical errors, think strategically, and make decisions quickly. “In chess, I am pretty universal, but definitely leaning towards positional rather than tactical play,” said Carlsen.

Discover what further analogies and insights Magnus Carlsen and Christian Pulisic have found during their conversation and how it is about for them to have a special signature PUMA shoe in the full video on PUMA’s official YouTube channel at: LINK.

Additionally, a collection of relevant photos from their interaction can be found HERE.

As the next step in the chess world, PUMA has partnered with Chess.com and Christian Pulisic once again to launch a Christian Pulisic chess bot. The Pulisic chess bot is an AI bot modeled after professional football player and global PUMA ambassador, Christian Pulisic. On July 13th, chess enthusiasts from around the globe will have the opportunity to test their skills and play a game against Pulisic. Fans can register for free on Chess.com and play Christian Pulisic from July 13th on the site’s “Play Computer” page, or at https://www.chess.com/play/computer?bot=christian-pulisic.

PUMA

PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.

Chess.com

Chess.com is the world's leading online chess platform, founded in 2005, dedicated to growing the game of chess and helping chess players around the world enjoy the game. Chess.com is the leading provider of chess gaming and other chess-related services including a vibrant forum and social network, a news feed, a chess academy, a coaching platform, tactics and puzzles, live tournaments, a separate website for kids (http://chesskid.com), and ChessTV. In May 2023, Chess.com‘s membership surpassed 140 million worldwide. In June 2023, Chess.com was named one of TIME's 100 Most Influential Companies.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:

P UMA
Gudrun Cämmerer
Teamhead Global Brand PR
gudrun.caemmerer@puma.com

Chess.com
Leon Watson
Head of PR, Chess.com
leon@chess.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Leaders of Dubai-Based Unicorns Hail City as Global Innovation Hub Shaping Future Technology and Driving the Digital Economy20.4.2026 16:08:00 EEST | Press release

Leaders of Dubai-based unicorn companies have reaffirmed the emirate’s status as a global hub for digital innovation and technology-led growth. The senior executives highlighted Dubai’s forward-looking regulatory environment, advanced infrastructure, and ability to attract international talent as key factors strengthening its appeal for high-growth digital businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420503062/en/ Leaders of Dubai-based unicorns hail city as global innovation hub shaping future technology and driving the digital economy (Photo: AETOSWire) They noted that Dubai has evolved into a strategic launchpad for ambitious companies, offering an agile business environment that supports innovation and enables expansion into regional and international markets. The business leaders also praised the strong alignment between the public and private sectors within Dubai’s digital ecosystem, supported by Dubai

Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 16:00:00 EEST | Press release

Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broadened the title’s availability by adding support for Nintendo Switch™ 2 at an early stage. As a res

Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 16:00:00 EEST | Press release

Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broadened the title’s availability by adding support for Nintendo Switch™ 2 at an early stage. As a res

Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 15:30:00 EEST | Press release

Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O

Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 15:30:00 EEST | Press release

Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye